AGTR2 and irritable bowel syndrome: Several preclinical studies have identified AT2 receptors on immune cells as therapeutic targets for analgesia [46,49,100]; moreover, recent reports have shown that naloxone suppresses the analgesic effects of AT2 receptor antagonists in irritable bowel syndrome-induced pain [102], indicating that AT2 signaling can also interfere with the opioid pathway.